XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.40

-0.6%

Jan 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (12361)	12/1/1999 11:13:00 PM
From: aknahow	Read Replies (1) of 17367

NEW NEW NEW NEW " An increasing number of antibiotic-resistant eye infections is causing concern in the ophthalmic community. In June 1999, XOMA began a partnership with Allergan to develop ophthalmic antiinfective products that combine rBPI with antibiotics. Both companies have confirmed earlier findings that rBPI synergizes with ofloxacin (an ocular antibiotic in widespread use) against various strains of gram-negative and gram-positive species of bacteria. The combination can, in many cases, reverse bacterial resistance to the antibiotic alone. Based on these findings Allergan is developing rBPI combination anti-infective products and is planning to enter clinical testing late in 2000 or early in 2001." Of course late 2000 or earl 2001 is a bit far off but the fact is we all knew it would take time and this is good news. The Mycoprex backgrounder also as a November 99 "date" notation indicating changes and additions to previous information. Suggest those with interest check out the site and post whatever changes they have noted that might be of interest to all. Do you think the XOMA webmaster worked late last night to make all these changes?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next